Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06780202 · ClinicalTrials.gov registry record · Phase 2
Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients
A Phase 2 study of Ankle Injuries and Disorders and Foot Injuries and Disorders, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 2
- Study locations
NCT06780202: Recruiting Phase 2 study of Ankle Injuries and Disorders and Foot Injuries and Disorders, sponsored by Emory University.
NCT06780202 is a Phase 2 study of Ankle Injuries and Disorders and Foot Injuries and Disorders that is actively recruiting participants, run by Emory University. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06780202, a Phase 2 study of Ankle Injuries and Disorders and Foot Injuries and Disorders, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries. The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes
Primary Outcome
The subjects will report nausea along the visual analog scale (VAS scale), which they will be educated on before surgery. A VAS for nausea is a straight line with one end labeled "no nausea" and the other end labeled "worst nausea imaginable". The patient marks a point on the line to indicate their nausea level. The distance from the "no nausea" end of the line is used to score the nausea intensity
Conditions Studied
Interventions
- DRUG medrol dosepak
- DRUG HYDROcodone Oral Tablet
Study Locations (2)
Georgia
- Emory Musculoskeletal Institute, Emory Orthopaedics & Spine Center - Atlanta
- Emory Sports Medicine Complex and Emory Orthopaedics and Spine Center - Johns Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06780202 shows while recruiting
NCT06780202 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 3 conditions, with Ankle Injuries and Disorders appearing as the primary indexed condition, and to 2 interventions - of which medrol dosepak is the first listed.
NCT06780202 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06780202 about?
NCT06780202 is a clinical study titled "Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients". This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries. The secondary objective of the study is to determine and monitor the effects of the course on complications ...
What is the current status of trial NCT06780202?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-01-27. Estimated completion is 2027-12.
What conditions does trial NCT06780202 study?
This clinical trial studies the following conditions: Ankle Injuries and Disorders, Foot Injuries and Disorders, Achilles Tendon Injury.
What interventions are being tested in trial NCT06780202?
The interventions under investigation include: medrol dosepak (DRUG), HYDROcodone Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06780202?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06780202 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ankle Injuries and Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06780202's enrollment target sits among peer trials
180 365th of 2000 higher than 1,611 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI